NGM Biopharmaceuticals (NGM) PT Raised to $30 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NGM Biopharmaceuticals (NGM) to Resume Trading at 8:30 am
February 24, 2020 8:26 AM ESTNGM Biopharmaceuticals (NASDAQ: NGM) to Resume Trading at 8:30 am
... MoreNGM Biopharmaceuticals (NGM) Phase 2 Study of Aldafermin in NASH Patients Shows Statistically Significant Achievement of Composite Endpoint
February 24, 2020 8:09 AM ESTClinically meaningful response rates of 38% of patients treated with aldafermin having liver fibrosis improvement of 1 stage and 24% of patients achieving resolution of NASH at 24 weeks--
--22% of aldafermin-treated patients versus 0% placebo achieved composite endpoint of both fibrosis improvement and resolution of NASH, a statistically significant result--
--Data support aldafermins differentiation in the NASH development landscape as a potential potent monotherapy that rapidly improves and sustains liver health with a favorable tolerability profile--
--Company to host conference call and webcast today at 8:30 a.m. ET (5:30 a.m.... More
